299 related articles for article (PubMed ID: 16120623)
1. Complete remission of brain metastases in three patients with stage IV melanoma treated with BOLD and G-CSF.
Bottoni U; Bonaccorsi P; Devirgiliis V; Panasiti V; Borroni RG; Trasimeni G; Clerico R; Calvieri S
Jpn J Clin Oncol; 2005 Sep; 35(9):507-13. PubMed ID: 16120623
[TBL] [Abstract][Full Text] [Related]
2. Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD), and human leukocyte interferon for metastatic uveal melanoma.
Pyrhönen S; Hahka-Kemppinen M; Muhonen T; Nikkanen V; Eskelin S; Summanen P; Tarkkanen A; Kivelä T
Cancer; 2002 Dec; 95(11):2366-72. PubMed ID: 12436444
[TBL] [Abstract][Full Text] [Related]
3. Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanoma.
O'Day SJ; Atkins MB; Boasberg P; Wang HJ; Thompson JA; Anderson CM; Gonzalez R; Lutzky J; Amatruda T; Hersh EM; Weber JS
J Clin Oncol; 2009 Dec; 27(36):6207-12. PubMed ID: 19917850
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy of disseminated melanoma with bleomycin, vincristine, CCNU, and DTIC (BOLD regimen). The Prudente Foundation Melanoma Study Group.
Cancer; 1989 May; 63(9):1676-80. PubMed ID: 2467736
[TBL] [Abstract][Full Text] [Related]
5. Lomustine (chloroethylnitrosourea [CCNU]), ifosfamide, bleomycin, vincristine, and cisplatin (CIBO-P) is an effective regimen for patients with poor prognostic refractory or multiple disease recurrent aggressive non-Hodgkin lymphoma.
Musolino A; Perrone MA; Michiara M; Delnevo D; Franciosi V; Di Blasio B; Ceci G; Camisa R; Ardizzoni A; Cocconi G
Cancer; 2005 May; 103(10):2109-17. PubMed ID: 15803492
[TBL] [Abstract][Full Text] [Related]
6. Palliative isolated limb perfusion for advanced limb disease in stage IV melanoma patients.
Takkenberg RB; Vrouenraets BC; van Geel AN; Nieweg OE; Noorda EM; Eggermont AM; Kroon BB
J Surg Oncol; 2005 Aug; 91(2):107-11. PubMed ID: 16028280
[TBL] [Abstract][Full Text] [Related]
7. Single-institution outcome of high-dose interleukin-2 (HD IL-2) therapy for metastatic melanoma and analysis of favorable response in brain metastases.
Powell S; Dudek AZ
Anticancer Res; 2009 Oct; 29(10):4189-93. PubMed ID: 19846971
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of neoadjuvant biochemotherapy for stage III melanoma.
Gibbs P; Anderson C; Pearlman N; LaClaire S; Becker M; Gatlin K; O'Driscoll M; Stephens J; Gonzalez R
Cancer; 2002 Jan; 94(2):470-6. PubMed ID: 11900232
[TBL] [Abstract][Full Text] [Related]
9. Metastatic malignant melanoma treated with procarbazine, vincristine and lomustine (POC).
Repetto L; Grimaldi A; Ardizzoni A; Sertoli MR; Rosso R
Chemioterapia; 1987 Feb; 6(1):63-5. PubMed ID: 3829137
[TBL] [Abstract][Full Text] [Related]
10. Dacarbazine DTIC and carboplatin as an outpatient treatment for disseminated malignant melanoma.
Nieboer P; Mulder NH; Van Der Graaf WT; Willemse PH; Hospers GA
Anticancer Res; 2001; 21(4B):3115-6. PubMed ID: 11712820
[TBL] [Abstract][Full Text] [Related]
11. Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD) plus interferon alpha for metastatic melanoma: a multicentre phase II study.
Punt CJ; van Herpen CM; Jansen RL; Vreugdenhil G; Muller EW; de Mulder PH
Br J Cancer; 1997; 76(2):266-9. PubMed ID: 9231931
[TBL] [Abstract][Full Text] [Related]
12. Combination chemotherapy with three marginally effective agents, CCNU, vincristine, and bleomycin, in the treatment of stage III melanoma.
De Wasch G; Bernheim J; Michel J; Lejeune F; Kenis Y
Cancer Treat Rep; 1976 Sep; 60(9):1273-6. PubMed ID: 65222
[TBL] [Abstract][Full Text] [Related]
13. Combination cytotoxic chemotherapy with procarbazine, vincristine, and lomustine (POC) in disseminated malignant melanoma: 8 years' follow-up.
Carmo-Pereira J; Costa FO; Henriques E
Cancer Treat Rep; 1984 Oct; 68(10):1211-4. PubMed ID: 6525593
[TBL] [Abstract][Full Text] [Related]
14. Lomustine, vincristine, and procarbazine in the treatment of metastatic malignant melanoma.
Shelley W; Quirt I; Bodurtha A; Iscoe N; Russell J; Paterson A; Young V
Cancer Treat Rep; 1985 Sep; 69(9):941-4. PubMed ID: 2992784
[TBL] [Abstract][Full Text] [Related]
15. Combined chemoradiation for the management of nasal natural killer (NK)/T-cell lymphoma: elucidating the significance of systemic chemotherapy.
Guo Y; Lu JJ; Ma X; Wang B; Hong X; Li X; Li J
Oral Oncol; 2008 Jan; 44(1):23-30. PubMed ID: 17306611
[TBL] [Abstract][Full Text] [Related]
16. Isolated limb infusion as palliative treatment for advanced limb disease in patients with AJCC stage IV melanoma.
Kroon HM; Lin DY; Kam PC; Thompson JF
Ann Surg Oncol; 2009 May; 16(5):1193-201. PubMed ID: 19224288
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of thalidomide in patients with brain metastases from malignant melanoma.
Vestermark LW; Larsen S; Lindeløv B; Bastholt L
Acta Oncol; 2008; 47(8):1526-30. PubMed ID: 18607876
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma.
Ott PA; Chang JL; Oratz R; Jones A; Farrell K; Muggia F; Pavlick AC
Chemotherapy; 2009; 55(4):221-7. PubMed ID: 19451711
[TBL] [Abstract][Full Text] [Related]
19. Organ- and treatment-specific local response rates to systemic and local treatment modalities in stage IV melanoma.
Richtig E; Ludwig R; Kerl H; Smolle J
Br J Dermatol; 2005 Nov; 153(5):925-31. PubMed ID: 16225601
[TBL] [Abstract][Full Text] [Related]
20. Pilot study of high-dose, concurrent biochemotherapy for advanced melanoma.
Kim KB; Eton O; East MJ; Hodges C; Papadopoulos NE; Grimm EA; Bedikian AY
Cancer; 2004 Aug; 101(3):596-603. PubMed ID: 15274073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
